When was Nuvation Bio founded?

Nuvation Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Nuvation Bio located?

Nuvation Bio is headquartered in New York City, United States.

How many employees does Nuvation Bio have?

As of Aug 31, 2026, the latest employee count at Nuvation Bio is 246.

Is Nuvation Bio a funded company?

Nuvation Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Oct 19, 2019.

When was the latest funding round of Nuvation Bio?

Nuvation Bio's latest funding was a $***** Series A round on Oct 19, 2019, with participation from 12 investors.

What is the annual revenue of Nuvation Bio?

Annual revenue of Nuvation Bio is between $50M and $100M as on Dec 31, 2025

Where does Nuvation Bio rank among its competitors?

Nuvation Bio ranks 74th amongst 3289 active competitors, of which 1119 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Nuvation Bio?

Nuvation Bio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Nuvation Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Nuvation Bio is a public company based in New York City (United States), founded in 2018 by David Hung. It operates as a Developer of therapeutics for cancer treatment. Nuvation Bio has raised $275M in funding from Omega Funds. The company has 3289 active competitors, including 1119 funded and 775 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Key Metrics

Founded Year

2018

Location

New York City, United States

Stage

Public

Total Funding

$275M in 1 round

Latest Funding Round

Series A, Oct 19, 2019, $*****

Investors

Omega Funds & 12 more

Ranked

74^th among 3289 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

246 as on Aug 31, 2026

Investment & Acquisitions

AnHeart Therapeutics

Similar Companies

Jazz Pharmaceuticals & 2981 more

Exit Details

Public

View Nuvation Bio's full profile

Nuvation Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Nuvation Bio Inc. CIN: 83-3460372 , United States, Active	Apr 23, 2018	$50M - $100M (As on Dec 31, 2025)	65 (As on Dec 31, 2021)	-

Nuvation Bio got listed on Feb 10, 2021.

Click here to take a look at Nuvation Bio's IPO in detail

Nuvation Bio has raised a total funding of $275M over 1 round. Its latest funding round was a Series A round on Oct 19, 2019 for $*****. 12 investors participated in its latest round. Nuvation Bio has 13 institutional investors.

Here is the list of recent funding rounds of Nuvation Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 19, 2019	8497965	Series A	6674768	3907664	4069764	7112852

Access funding benchmarks and valuations. Sign up today!

View details of Nuvation Bio's funding rounds and investors

The founders of Nuvation Bio is David Hung.

Here are the details of Nuvation Bio's key team members:

David Hung: Founder & CEO of Nuvation Bio.

View details of Nuvation Bio's Founder profiles and Board Members

Nuvation Bio's employee count trend

Nuvation Bio has 246 employees as of Aug 26. Here is Nuvation Bio's employee count trend over the years:

Uncover Nuvation Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nuvation Bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Nuvation Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
74th	Nuvation Bio 2018, New York City (United States), Public	Developer of therapeutics for cancer treatment	$275M	Boxer Capital, Aisling Capital & 11 others	64/100